Lung Cancer Trial, Not Yet Recruiting NCT03514329 Sponsor: Uptake Medical Technology, Inc. Condition: Lung Cancer
Back to Lung Cancer

Lung Cancer Trial, Not Yet Recruiting

NCT03514329
Not Yet Recruiting Not Applicable

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • The person must be 18 years of age or older.
  • A doctor has recommended ablation (a non-surgical procedure to destroy abnormal tissue) or an alternative to surgery for the person's condition.
  • The person has either a non-small cell lung cancer tumour measuring 2cm or smaller (at an early, localised stage), or one or more lung tumours that have spread from another part of the body, also measuring 2cm or smaller.
  • Lab testing has confirmed the presence of cancer cells.
  • The tumour is located in the outer third of the lung (the peripheral area, away from the centre).
  • The entire tumour margin can be targeted with a maximum of three applications of the vapour ablation treatment, based on the treatment plan.
  • The person has read and signed a consent form agreeing to take part in the trial.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • The tumour is located in a central area of the chest, touching structures such as the main airway, main lung blood vessels, food pipe, or windpipe.
  • The person has a carcinoid type of lung tumour.
  • The tumour is linked to a collapsed area of the lung, lung inflammation caused by a blockage, or fluid around the lung.
  • Lung function test results fall below certain minimum levels — specifically, a breathing measurement called FEV1 is below 20% of the expected value, or a measurement of how well the lungs transfer oxygen into the blood (DLCO) is below 20% of the expected value.
  • The person requires supplemental oxygen at any time, whether at rest or during physical activity.
  • The person has been hospitalised for a heart-related condition within the past 6 months.
  • Certain liver-related blood test results are higher than 1.5 times the upper limit of the normal range.
  • A kidney function blood test result (serum creatinine) is above 2 mg/dL.
  • The person has had an infection within the past 30 days.
  • The person is currently taking medication that suppresses the immune system, or is taking prednisone (a steroid) at a dose above 10mg per day or an equivalent amount of a similar medication.
  • The person has an existing implant inside the airways that would block the path to the tumour.
  • The person is pregnant, breastfeeding, or is of childbearing potential and is not using a reliable form of contraception.
  • The person has a blood clotting disorder, a history of severe coughing up of blood, or is currently taking blood-thinning medication. (Note: certain anti-platelet medications may be permitted if they can be stopped at least 7 days before and 10 days after the procedure — confirm with trial site.)
  • In the opinion of the trial investigators, the person has any condition that could affect their safety or the reliability of the trial results.
  • In the opinion of the trial investigators, any characteristic of the tumour could affect the person's safety or the reliability of the trial results.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 15 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 650-823-9093

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Not Applicable
Sponsor
Uptake Medical Technology, Inc.
Registry
ClinicalTrials.gov
Start date
1 September 2026
Est. completion
30 March 2028

Where this trial is recruiting

🇦🇹 Austria 🇮🇹 Italy

Primary endpoints

BTVA-C related AEs/SAEs; Successful BTVA-C Treatment Delivery; Local Control Evaluation per RECIST

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov